(Q32043207)

English

Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

B Seignères

1

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

S Aguesse-Germon

2

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

C Pichoud

3

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

I Vuillermoz

4

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

C Jamard

5

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

C Trépo

6

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

F Zoulim

7

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

publication date

1 January 2001

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Journal of Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

114-122

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B reactivation after lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine therapy of WHV-infected woodchucks.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Replication of DHBV genomes with mutations at the sites of initiation of minus- and plus-strand DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitory Effect of Penciclovir-Triphosphate on Duck Hepatitis B Virus Reverse Transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Homologous recombination between hepadnaviral genomes following in vivo DNA transfection: implications for studies of viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900074-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(00)00074-X

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q32043207&oldid=1994260147"